Myburgh 1995.

Methods	open randomized crossover trial. After 4 weeks run‐in phase, patients received ramipril in the morning and at bedtime each for 4 weeks Sample size calculation: not reported carryover effects: not reported no washout period between treatment arms
Participants	Country: South African Number randomised: 39 gender: 35 men, 4 women age range: 24‐73 years mean age: 49 years Ethnicity: not reported inclusion criteria: sitting DBP≥95 mm Hg and <114 mm Hg exclusion criteria: not stated
Interventions	2.5 mg od ramipril taken at 8 AM to 11AM or at 8 PM to 11PM
Outcomes	Mortality: not reported Morbidity: not reported Blood Pressure data:24h BP change by 24h ABPM, data was obtained from graph and text (fig 1 on page 1302 and fig 2 on page 1303) Adverse Events: withdrawals due to adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	not reported
Allocation concealment (selection bias)	Unclear risk	not reported
Blinding (performance bias and detection bias) All outcomes	High risk	open label
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were reported. Three patients was excluded due to increase dose of ramipril to 5 mg, three patients withdrawn because of adverse events
Selective reporting (reporting bias)	High risk	Morning SBP, DBP were not reported
Other bias	Unclear risk	carryover effects were not reported